The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs,

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

Evercore ISI raised the firm’s price target on CVS Health (CVS) to $65 from $60 and keeps an Outperform rating on the shares. Given 2025 will

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc ... organ transplants and other conditions and procedures, the FTC said. The report demonstrates how pharmacy benefit managers influence every aspect of the pharmaceutical ...

TD Cowen analyst Ryan Langston maintained a Buy rating on Cigna (CI – Research Report) today and set a price target of $391.00. The company’s

However, its low valuation could have investors wondering if now is the right time to take a chance on the business, especially before it releases its year-end earnings numbers on Feb. 12. Let's take a look at whether CVS could potentially be an underrated buy right now.

At least one Woodward pharmacist is celebrating an action by Oklahoma Attorney General Gentner Drummond that could turn the tide for area pharmacists, some who are struggling to stay in

Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in anticipation of future performance dynamics,

At least one Woodward pharmacist is celebrating an action by Oklahoma Attorney General Gentner Drummond that could turn the tide for area pharmacists, some who are struggling stay in business

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without many pharmacy options.